ADHD drugs not associated with serious CV events in children
- PDF / 170,198 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 114 Downloads / 207 Views
1
ADHD drugs not associated with serious CV events in children Attention-deficit hyperactivity disorder (ADHD) medication does not appear to be associated with serious cardiovascular (SCV) events in children or adolescents with ADHD or autism spectrum disorder (ASD), according to findings of a F. HoffmannLa Roche-funded study published in CNS Drugs. Commercial claims data (2000–2016) and Medicaid claims data (2012–2016) from the US Truven Health MarketScan database were used to conduct nested case–control studies in paediatric patients 3–18 years of age with ADHD (n=2 240 774) or ASD (326 221). Each case with the composite outcome of stroke, myocardial infarction (MI) or serious arrhythmias was matched with ten controls based on age, sex and insurance type. Conditional logistic regression analysis was used to evaluate the associations between SCV events and current ADHD medication use including CNS stimulants such as methylphenidate or non-stimulants such as atomoxetine. The risk of SCV events was not significantly increased in patients with ADHD or ASD; in the ADHD cohort 33.9% of cases and 32.2% of controls were exposed to ADHD medication (odds ratio [OR] 1.08; 95% CI 0.78, 1.49), while in the ASD cohort 12.5% of cases and 22.1% of controls were exposed to ADHD drugs (OR 0.49; 95% CI 0.20, 1.20). There was also no increased risk of SCV events after adjustment for covariates, or for individual SCV outcomes. "In conclusion, in a large, contemporary insurance database, we found low rates of SCV events in children and adolescents with ADHD (3.1/100,000 person years) and ASD (5.6/100,000 person years). Furthermore, we found no evidence of an increased SCV risk when exposed to ADHD medications," said the authors. Houghton R, et al. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder. CNS Drugs : 25 Nov 2019. Available from: URL: http://doi.org/10.1007/ 803439018 s40263-019-00686-4
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
